Dmitri Bobilev
Hoofd Techniek/Wetenschap/O&O bij FUSN PHAR
Vermogen: - $ op 30-04-2024
Profiel
Dmitri Bobilev is currently the Chief Medical Officer at Fusion Pharmaceuticals, Inc. Prior to his current position, he worked as the Head of Clinical Development and Vice President at Vedanta Biosciences, Inc. from 2018 to 2020.
He also held the position of Vice President and Head of Clinical Development at Checkmate Pharmaceuticals, Inc. Dr. Bobilev earned a doctorate degree from Omsk State Medical Academy.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
04-01-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Dmitri Bobilev
Bedrijven | Functie | Begin |
---|---|---|
FUSN PHAR | Hoofd Techniek/Wetenschap/O&O | 07-11-2022 |
Eerdere bekende functies van Dmitri Bobilev
Bedrijven | Functie | Einde |
---|---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-08-2020 |
CHECKMATE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Dmitri Bobilev
Omsk State Medical Academy | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
FUSN PHAR | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |